Baxter International Inc.

baxter.com

Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products. For more than 85 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

WESTLAKE VILLAGE BIOPARTNERS LAUNCHES TWO NEW FUNDS TOTALING $500 MILLION TO BUILD AND INVEST IN PROMISING LIFE SCIENCES COMPANIES

Westlake Village BioPartners | December 15, 2020

news image

Westlake Village BioPartners today announced the launch of two new funds totaling $500 million to build and put resources into promising life sciences organizations with transformative therapeutic technologies. The first fund, known as Opportunity 1, is $70 million and permits Westlake to contribute extra Series B or later-round capital into promising organizations they incubated or invested into with their original fund, Westlake BioPartners 1 (WBP1). One example is a begin...

Read More

Cell and Gene Therapy

EXUMA BIOTECH COMPLETES SERIES B2 TO ADVANCE NOVEL CELL & GENE THERAPIES

EXUMA Biotech Corp. | December 22, 2021

news image

EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies and delivery solutions for liquid and solid tumors, announced the completion of a $41 million Series B2 financing. The Series B2 brings the total capital raised since its inception to approximately $130 million. Proceeds will be used to support further development of EXUMA's autologous subcutaneous rPOC CAR-TaNK platform for hematologic and solid tumors and con...

Read More

Research

ASIA'S FIRST INDUSTRIAL INSECT COMPANY, NUTRITION TECHNOLOGIES, CLOSES US$20M EQUITY ROUND TO LAUNCH NEW PRODUCTS AND EXPAND INTO NEW MARKETS

Nutrition Technologies | September 19, 2022

news image

On 19th September 2022 Nutrition Technologies completed an equity venture round of US$ 20m. The round was led by PTT Ventures and supported by Sumitomo Corporation, ING Sustainable Investments, Mandala Capital, as well as continued participation from existing investors: Openspace Ventures, SEEDs Capital and Hera Capital. The round was advised by ING Corporate Finance. The proceeds will be used to fund an expansion into new markets; launch new products; accelerate R&D; and create new strategi...

Read More

GENE THERAPY OFFERS HOPE FOR UNTREATABLE CTE BRAIN DISORDER

Genetic Literacy Project | January 14, 2020

news image

Researchers from Weill Cornell Medical College published a new study (“Anti-Phospho-Tau Gene Therapy for Chronic Traumatic Encephalopathy”) in Human Gene Therapy that shows the feasibility of using gene therapy to treat the progressive neurodegenerative disorder chronic traumatic encephalopathy (CTE). The study demonstrated the effectiveness of direct delivery of gene therapy into the brain of a mouse model of CTE....

Read More
news image

Medical

WESTLAKE VILLAGE BIOPARTNERS LAUNCHES TWO NEW FUNDS TOTALING $500 MILLION TO BUILD AND INVEST IN PROMISING LIFE SCIENCES COMPANIES

Westlake Village BioPartners | December 15, 2020

Westlake Village BioPartners today announced the launch of two new funds totaling $500 million to build and put resources into promising life sciences organizations with transformative therapeutic technologies. The first fund, known as Opportunity 1, is $70 million and permits Westlake to contribute extra Series B or later-round capital into promising organizations they incubated or invested into with their original fund, Westlake BioPartners 1 (WBP1). One example is a begin...

Read More
news image

Cell and Gene Therapy

EXUMA BIOTECH COMPLETES SERIES B2 TO ADVANCE NOVEL CELL & GENE THERAPIES

EXUMA Biotech Corp. | December 22, 2021

EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies and delivery solutions for liquid and solid tumors, announced the completion of a $41 million Series B2 financing. The Series B2 brings the total capital raised since its inception to approximately $130 million. Proceeds will be used to support further development of EXUMA's autologous subcutaneous rPOC CAR-TaNK platform for hematologic and solid tumors and con...

Read More
news image

Research

ASIA'S FIRST INDUSTRIAL INSECT COMPANY, NUTRITION TECHNOLOGIES, CLOSES US$20M EQUITY ROUND TO LAUNCH NEW PRODUCTS AND EXPAND INTO NEW MARKETS

Nutrition Technologies | September 19, 2022

On 19th September 2022 Nutrition Technologies completed an equity venture round of US$ 20m. The round was led by PTT Ventures and supported by Sumitomo Corporation, ING Sustainable Investments, Mandala Capital, as well as continued participation from existing investors: Openspace Ventures, SEEDs Capital and Hera Capital. The round was advised by ING Corporate Finance. The proceeds will be used to fund an expansion into new markets; launch new products; accelerate R&D; and create new strategi...

Read More
news image

GENE THERAPY OFFERS HOPE FOR UNTREATABLE CTE BRAIN DISORDER

Genetic Literacy Project | January 14, 2020

Researchers from Weill Cornell Medical College published a new study (“Anti-Phospho-Tau Gene Therapy for Chronic Traumatic Encephalopathy”) in Human Gene Therapy that shows the feasibility of using gene therapy to treat the progressive neurodegenerative disorder chronic traumatic encephalopathy (CTE). The study demonstrated the effectiveness of direct delivery of gene therapy into the brain of a mouse model of CTE....

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us